In conclusion, CXCL13 appears to be a useful marker for categorising heterogeneous patients with CVID into those without immune dysregulation-related complications (“normal” serum CXCL13) and those with a complex clinical and immune phenotype (“high” serum CXCL13). The gene discussed is CXCL13; the disease is common variable immunodeficiency.